News

Deepak Bhatt, MD, MPH, MBA, discusses a group of 4 high-impact studies from ESC Congress 2024: FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI.

In an interview with HCPLive, Wadden discussed the findings of a post-hoc analysis, supporting how semaglutide is not linked to an increased suicidal ideation risk.

The August 2024 month in review highlights our coverage of pipeline news, a cross-specialty feature about dialysis, and other recent renal news and research from the past few weeks.

The biosimilars month in review highlights recent data demonstrating clinical equivalence and efforts to improve their access.

Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.

A post-hoc analysis of the STEP trials found semaglutide for weight management doesn’t increase depression or suicidal thoughts in individuals without major mental disorders.

This August 2024 month in review spotlights HCPLive’s top coverage of hepatic pipeline news and recent research in liver disease, HCV, and more.

The FDA approved neffy for treating severe allergic reactions in people over 33 kg in August 2024.

This August 2024 month in review highlights new recommendations from the USPSTF, FDA approval of a treatment for chronic GVHD, and Phase 2 data for severe HDFN.

Ahmad Masri, MD, MS, discusses the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in HCM.

This month in review highlights MDMA-assisted therapy coverage, experiences with zuranolone a year after its approval, and early positive data on potential treatments.

Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN.

This month in review highlights the top sleep stories in August, from sleep health in patients undergoing dialysis to the benefits of catching up on sleep.

Ahmad Masri, MD, MS, discusses an integrated safety analysis of aficamten using data from 3 clinical trials.

The decision to revoke the conditional marketing authorization is based on a June 2024 CHMP recommendation from the EMA suggesting the benefits of Ocaliva do not outweigh its risks.

Patients receiving Humira or Hulio had the highest satisfaction levels across different measures.

This August 2024 month in review highlights updates to the ophthalmic pipeline, metformin for geographic atrophy, and decreasing rates of postoperative endophthalmitis in the US.

In this review of August 2024, the editorial team highlighted major stories from the previous month related to FDA approvals and medications for atopic dermatitis and psoriasis.

Siddharth Patel, MD, MPH, discusses how an AZALEA-TIMI 71 analysis presented at ESC Congress 2024.

A study suggests transient elastography and fibrosis-4 index may be effective in predicting hepatocellular carcinoma risk in hepatitis C patients.

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

EMPACT-MI study shows empagliflozin is safe post-acute MI and reduces heart failure events, with kidney protection across kidney function levels.

In this episode, Muthiah Vadugnathan, MD, MPH, and Stephen Greene, MD, discuss finerenone and MRA data from ESC Congress 2024.

ESC 2024: Phase 3 PALISADE trial shows plozasiran significantly lowers triglycerides and pancreatitis risk in FCS; NDA planned by year-end.

Kausik Ray, MD, MPhil, discusses the results of the INTERASPIRE study and how it improves our understanding of the effects of elevated Lp(a).

Matthew Cavender, MD, MPH, discusses a study he led at ESC Congress examining utility of the SCORE2-Diabetes risk score using clinical trial data.

MAVA-LTE trial data show mavacamten's sustained benefits in symptomatic obstructive HCM, with long-term improvements in LVOT, NT-proBNP, and quality of life.

A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.